DSE News Archive of Dhaka Stock Market

Wed, 30th April 2025

10:31 am

Q3 Financials

(Cont. news of TECHNODRUG): The company's EPS, Cash Flow from Operation and NAV are 1.41, 0.15 and 30.24 respectively in July-24 to March-25 (9 month) against 2.58, 2.94 and 33.50 in the July-23 to March-24 (9 month) of previous period. So, there is significant deviation in EPS, Cash Flow from Operation and NAV. This is because sales have come down to Tk. 259.39 crore from Tk. 308.04 crore in the current period than previous period. (cont.2)

Wed, 30th April 2025

4:04 am

Q3 Financials

(Cont. news of TECHNODRUG): The reason behind of low sales value is Government did not procure as much as they did in the last year. The company mostly sell to contraceptive items to Government and Government is their large buyer of these items. In addition, the company recently issued shares for IPO, resulting in increasing 3,78,40,788 shares. These increased shares also played a part. Altogether resulted in reducing EPS, Cash Flow from Operation and NAV in this period. (end)

Wed, 30th April 2025

4:04 am

Q3 Financials

(Cont. news of TECHNODRUG): The company?s EPS, Cash Flow from Operation and NAV are 1.41, 0.15 and 30.24 respectively in July-24 to March-25 (9 month) against 2.58, 2.94 and 33.50 in the July-23 to March-24 (9 month) of previous period. So, there is significant deviation in EPS, Cash Flow from Operation and NAV. This is because sales have come down to Tk. 259.39 crore from Tk. 308.04 crore in the current period than previous period. (cont.2)

Wed, 30th April 2025

4:04 am

Q3 Financials

(Q3 Un-audited): EPS was Tk. 0.33 for January-March 2025 as against Tk. 0.42 for January-March 2024; EPS was Tk. 1.41 for July 2024-March 2025 as against Tk. 2.58 for July 2023-March 2024. NOCFPS was Tk. 0.15 for July 2024-March 2025 as against Tk. 2.94 for July 2023-March 2024. NAV per share (with revaluation) was Tk. 30.24 as on March 31, 2025 and Tk. 33.50 as on June 30, 2024. NAV per share (without revaluation) was Tk. 26.55 as on March 31, 2025 and Tk. 28.33 as on June 30, 2024. (cont.1)

Wed, 23rd April 2025

6:29 am

Board Meeting schedule under LR 16(1)

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 29, 2025 at 4:30 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2025.

Thu, 20th February 2025

7:54 am

Auditor's report regarding status of IPO Proceeds utilization

Techno Drugs Ltd. submitted auditor's report regarding status of IPO (Initial Public Offering) Proceeds utilization statement for the quarter ended December 31, 2024. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2024/TECHNODRUGS_2024.pdf

Mon, 3rd February 2025

10:31 am

Category Change

The Company will be placed in 'A' category from existing 'N' category with effect from February 04, 2025 as the Company has reported disbursement of 12% Cash Dividend for the year ended June 30, 2024.

Mon, 3rd February 2025

6:34 am

Dividend Disbursement

The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2024 to the respective shareholders.

Sun, 2nd February 2025

4:04 am

Q2 Financials

(cont. news of TECHNODRUG): The reason behind of low sales value is Government did not procure as much as they did in the last year. The company mostly sell to contraceptive items to Government and Government is their large buyer of these items. In addition, the company recently issued shares for IPO, resulting in increasing 3,78,40,788 shares. These increased shares also played a part. Altogether resulted in reducing EPS, Cash Flow from Operation and NAV in the second quarter. (end)

Sun, 2nd February 2025

4:04 am

Q2 Financials

(cont. news of TECHNODRUG): Reasons for significant variance: The company's EPS, Cash Flow from Operation and NAV are 1.08, 0.19 and 29.91 respectively in July to December 2024 against 2.16, 1.23 and 33.50 in the previous period July to December 2023. So, there is significant deviation in EPS, Cash Flow from Operation and NAV. This is because sales have come down to Tk. 193 crore from Tk. 255 crore in the current period than the previous period. (cont.2)

Sun, 2nd February 2025

4:04 am

Q2 Financials

(Q2 Un-audited): Basic EPS was Tk. 0.48 for October-December 2024 as against Tk. 1.07 for October-December 2023; EPS was Tk. 1.08 for July-December 2024 as against Tk. 2.16 for July-December 2023. NOCFPS was Tk. 0.19 for July-December 2024 as against Tk. 1.23 for July-December 2023. NAV per share (with revaluation) was Tk. 29.91 as on December 31, 2024 and Tk. 33.50 as on June 30, 2024. NAV per share (without revaluation) was Tk. 26.22 as on December 31, 2024 and Tk. 28.33 as on June 30, 2024. (cont.1)

Mon, 27th January 2025

5:04 am

Board Meeting schedule under LR 16(1)

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 30, 2025 at 4:30 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2024.

Mon, 18th November 2024

7:39 am

Resumption after Record Date

Trading of the shares of the company will resume on 19.11.2024.

Sun, 17th November 2024

7:59 am

Suspension for Record date

Trading of the shares of the company will remain suspended on record date i.e., 18.11.2024.

Sun, 17th November 2024

4:04 am

Q1 Financials

(Continuation news of TECHNODRUG): This is because sales have come down to Tk. 102 crore from Tk. 145 crore in the first quarter than the first quarter of previous year. The reason behind of low sales value is Government did not procure as much as they did in the last year. In addition, recently issued shares for IPO, resulting in increasing 3,78,40,788 shares. These increased shares also played a part. Altogether resulted in reducing EPS, Cash Flow from Operation and NAV in the first quarter. (end)

Sun, 17th November 2024

4:04 am

Q1 Financials

(Q1 Un-audited): EPS was Tk. 0.63 for July-September, 2024 as against Tk. 1.09 for July-September, 2023; NOCFPS was Tk. 0.23 for July-September, 2024 as against Tk. 1.51 for July-September, 2023. NAV per share (with revaluation) was Tk. 29.88 as on September 30, 2024 and Tk. 33.50 as on June 30, 2024. NAV per share (without revaluation) was Tk. 26.19 as on September 30, 2024 and Tk. 28.33 as on June 30, 2024. Reasons for significant deviation in EPS, NOCFPS and NAVPS: (cont.)

Wed, 13th November 2024

6:34 am

Spot News

Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 14.11.2024 to 17.11.2024 and trading of the shares of the company will remain suspended on record date i.e., 18.11.2024.

Mon, 11th November 2024

5:09 am

Board Meeting schedule under LR 16(1)

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 14, 2024 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2024.

Mon, 28th October 2024

10:31 am

Credit Rating Result

Emerging Credit Rating Limited (ECRL) has affirmed surveillance rating of the Company as "A-" in the long term and "ST-3" in the short term along with a Stable outlook based on audited financial statements of FY 2020-2023, Nine months unaudited financial statements up to march 31, 2024 and other quantitative information available up to the date of rating.

Mon, 28th October 2024

4:04 am

Price Limit Open

There will be no price limit on the trading of the shares of the Company today (28.10.2024) following its corporate declaration.

Mon, 28th October 2024

4:04 am

Dividend Declaration

(Continuation news of TECHNODRUG): 160/A, Kakrail VIP Road, Dhaka 1000 and Digital Platform through the link https://technodrug.digitalagmbd.net. Record date: 18.11.2024. The Company has also reported EPS of Tk. 2.94, NAV per share with revaluation of Tk. 33.50, NAV per share without revaluation of Tk. 28.33 and NOCFPS of Tk. 4.48 for the year ended June 30, 2024 as against Tk. 2.08, Tk. 27.74, Tk. 22.57 and Tk. 2.23 respectively for the year ended June 30, 2023. (end)

Mon, 28th October 2024

4:04 am

Dividend Declaration

The Board of Directors has recommended 12% Cash Dividend only for general shareholders other than Board of Directors for the year ended June 30, 2024. Directors/ sponsor are holding 82,776,200 shares and General Public are holding 49,221,988 shares. Cash dividend payable to General Public is Tk. 59,066,386.00. Date of AGM: 26.12.2024, Time: 10:00 AM, Venue: The AGM will be conducted through Hybrid System in combination of Physical Presence at Institution of Diploma Engineers, (cont.)

Mon, 21st October 2024

4:59 am

Board Meeting schedule under LR 19(1)

As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 27, 2024 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2024.

Sun, 14th July 2024

4:05 am

Q3 Financials of Techno Drugs Limited

(Continuation news of TECHNODRUG): Pre-IPO weighted average paid-up number of shares for 03 (three) months (January-March, 2024) and 09 (nine) months (July'23- March'24) period ended on 31 March 2024 was 94,157,400 which was same for the same period of the previous year. However, Post-IPO paid-up number of shares would be 131,998,188. (end)

Sun, 14th July 2024

4:05 am

Q3 Financials of Techno Drugs Limited

(Continuation news of TECHNODRUG): Pre-IPO Net Asset Value (NAV) per share with revaluation reserve (considering Pre-IPO paid up shares) would be BDT 30.32 as on 31 March 2024 and the same would be BDT 29.21 (considering Post-IPO paid up shares). Pre-IPO Net Asset Value (NAV) per share without revaluation reserve (considering Pre-IPO paid up shares) would be BDT 25.15 as on 31 March 2024 and the same would be BDT 25.51 (considering Post-IPO paid up shares). (cont.3)

Sun, 14th July 2024

4:05 am

Q3 Financials of Techno Drugs Limited

(Continuation news of TECHNODRUG): Moreover, profit after tax was BDT 242.93 million and basic EPS of BDT 2.58 for the 9 (nine) months (July'23-March'24) period ended on 31 March 2024 as against profit after tax of BDT 178.53 million and basic EPS of BDT 1.90 for the same period of the previous year. However, Post-IPO EPS would be BDT 1.84 for 09 (nine) months (July'23- March'24) period ended on 31 March 2024. (cont.2)

Sun, 14th July 2024

4:05 am

Q3 Financials of Techno Drugs Limited

Techno Drugs Limited: (Q3): As per un-audited Q3 financial statements, profit after tax was BDT 39.13 million and basic EPS BDT 0.42 for the 03 (three) months (January-March, 2024) period ended on 31 March 2024 as against profit after tax of BDT 29.59 million and basic EPS of BDT 0.31 for the same period of the previous year. However, Post-IPO basic EPS for the 03 (three) months (January-March 2024) period ended on 31 March 2024 would be BDT 0.30. (cont.1)

Sun, 14th July 2024

4:05 am

Prohibition on providing loan facilities to purchase securities

DSE NEWS: The Stock Brokers, Merchant Bankers and Portfolio Managers are requested to abstain from providing loan facilities to purchase securities of Techno Drugs Ltd. in between 1st to 30th trading day starting from today i.e., July 14, 2024 as per BSEC Directive No. BSEC/CMRRCD/2009-193/32 dated December 26, 2021.

Sun, 14th July 2024

4:05 am

Trading of Shares of Techno Drugs Limited

Trading of shares of Techno Drugs Limited will start from today i.e., July 14, 2024 under the main market of DSE. Trading Code and Company code for Techno Drugs Limited at DSE will be "TECHNODRUG" and "18499" respectively under "Pharmaceuticals & Chemicals" Sector.

Wed, 30th April 2025

10:31 am

Q3 Financials

(Cont. news of TECHNODRUG): The company's EPS, Cash Flow from Operation and NAV are 1.41, 0.15 and 30.24 respectively in July-24 to March-25 (9 month) against 2.58, 2.94 and 33.50 in the July-23 to March-24 (9 month) of previous period. So, there is significant deviation in EPS, Cash Flow from Operation and NAV. This is because sales have come down to Tk. 259.39 crore from Tk. 308.04 crore in the current period than previous period. (cont.2)

Wed, 30th April 2025

4:04 am

Q3 Financials

(Cont. news of TECHNODRUG): The reason behind of low sales value is Government did not procure as much as they did in the last year. The company mostly sell to contraceptive items to Government and Government is their large buyer of these items. In addition, the company recently issued shares for IPO, resulting in increasing 3,78,40,788 shares. These increased shares also played a part. Altogether resulted in reducing EPS, Cash Flow from Operation and NAV in this period. (end)

Wed, 30th April 2025

4:04 am

Q3 Financials

(Cont. news of TECHNODRUG): The company?s EPS, Cash Flow from Operation and NAV are 1.41, 0.15 and 30.24 respectively in July-24 to March-25 (9 month) against 2.58, 2.94 and 33.50 in the July-23 to March-24 (9 month) of previous period. So, there is significant deviation in EPS, Cash Flow from Operation and NAV. This is because sales have come down to Tk. 259.39 crore from Tk. 308.04 crore in the current period than previous period. (cont.2)

Wed, 30th April 2025

4:04 am

Q3 Financials

(Q3 Un-audited): EPS was Tk. 0.33 for January-March 2025 as against Tk. 0.42 for January-March 2024; EPS was Tk. 1.41 for July 2024-March 2025 as against Tk. 2.58 for July 2023-March 2024. NOCFPS was Tk. 0.15 for July 2024-March 2025 as against Tk. 2.94 for July 2023-March 2024. NAV per share (with revaluation) was Tk. 30.24 as on March 31, 2025 and Tk. 33.50 as on June 30, 2024. NAV per share (without revaluation) was Tk. 26.55 as on March 31, 2025 and Tk. 28.33 as on June 30, 2024. (cont.1)

Sun, 2nd February 2025

4:04 am

Q2 Financials

(cont. news of TECHNODRUG): The reason behind of low sales value is Government did not procure as much as they did in the last year. The company mostly sell to contraceptive items to Government and Government is their large buyer of these items. In addition, the company recently issued shares for IPO, resulting in increasing 3,78,40,788 shares. These increased shares also played a part. Altogether resulted in reducing EPS, Cash Flow from Operation and NAV in the second quarter. (end)

Sun, 2nd February 2025

4:04 am

Q2 Financials

(cont. news of TECHNODRUG): Reasons for significant variance: The company's EPS, Cash Flow from Operation and NAV are 1.08, 0.19 and 29.91 respectively in July to December 2024 against 2.16, 1.23 and 33.50 in the previous period July to December 2023. So, there is significant deviation in EPS, Cash Flow from Operation and NAV. This is because sales have come down to Tk. 193 crore from Tk. 255 crore in the current period than the previous period. (cont.2)

Sun, 2nd February 2025

4:04 am

Q2 Financials

(Q2 Un-audited): Basic EPS was Tk. 0.48 for October-December 2024 as against Tk. 1.07 for October-December 2023; EPS was Tk. 1.08 for July-December 2024 as against Tk. 2.16 for July-December 2023. NOCFPS was Tk. 0.19 for July-December 2024 as against Tk. 1.23 for July-December 2023. NAV per share (with revaluation) was Tk. 29.91 as on December 31, 2024 and Tk. 33.50 as on June 30, 2024. NAV per share (without revaluation) was Tk. 26.22 as on December 31, 2024 and Tk. 28.33 as on June 30, 2024. (cont.1)

Sun, 17th November 2024

4:04 am

Q1 Financials

(Continuation news of TECHNODRUG): This is because sales have come down to Tk. 102 crore from Tk. 145 crore in the first quarter than the first quarter of previous year. The reason behind of low sales value is Government did not procure as much as they did in the last year. In addition, recently issued shares for IPO, resulting in increasing 3,78,40,788 shares. These increased shares also played a part. Altogether resulted in reducing EPS, Cash Flow from Operation and NAV in the first quarter. (end)

Sun, 17th November 2024

4:04 am

Q1 Financials

(Q1 Un-audited): EPS was Tk. 0.63 for July-September, 2024 as against Tk. 1.09 for July-September, 2023; NOCFPS was Tk. 0.23 for July-September, 2024 as against Tk. 1.51 for July-September, 2023. NAV per share (with revaluation) was Tk. 29.88 as on September 30, 2024 and Tk. 33.50 as on June 30, 2024. NAV per share (without revaluation) was Tk. 26.19 as on September 30, 2024 and Tk. 28.33 as on June 30, 2024. Reasons for significant deviation in EPS, NOCFPS and NAVPS: (cont.)

Sun, 14th July 2024

4:05 am

Q3 Financials of Techno Drugs Limited

(Continuation news of TECHNODRUG): Pre-IPO weighted average paid-up number of shares for 03 (three) months (January-March, 2024) and 09 (nine) months (July'23- March'24) period ended on 31 March 2024 was 94,157,400 which was same for the same period of the previous year. However, Post-IPO paid-up number of shares would be 131,998,188. (end)

Sun, 14th July 2024

4:05 am

Q3 Financials of Techno Drugs Limited

(Continuation news of TECHNODRUG): Pre-IPO Net Asset Value (NAV) per share with revaluation reserve (considering Pre-IPO paid up shares) would be BDT 30.32 as on 31 March 2024 and the same would be BDT 29.21 (considering Post-IPO paid up shares). Pre-IPO Net Asset Value (NAV) per share without revaluation reserve (considering Pre-IPO paid up shares) would be BDT 25.15 as on 31 March 2024 and the same would be BDT 25.51 (considering Post-IPO paid up shares). (cont.3)

Sun, 14th July 2024

4:05 am

Q3 Financials of Techno Drugs Limited

(Continuation news of TECHNODRUG): Moreover, profit after tax was BDT 242.93 million and basic EPS of BDT 2.58 for the 9 (nine) months (July'23-March'24) period ended on 31 March 2024 as against profit after tax of BDT 178.53 million and basic EPS of BDT 1.90 for the same period of the previous year. However, Post-IPO EPS would be BDT 1.84 for 09 (nine) months (July'23- March'24) period ended on 31 March 2024. (cont.2)

Sun, 14th July 2024

4:05 am

Q3 Financials of Techno Drugs Limited

Techno Drugs Limited: (Q3): As per un-audited Q3 financial statements, profit after tax was BDT 39.13 million and basic EPS BDT 0.42 for the 03 (three) months (January-March, 2024) period ended on 31 March 2024 as against profit after tax of BDT 29.59 million and basic EPS of BDT 0.31 for the same period of the previous year. However, Post-IPO basic EPS for the 03 (three) months (January-March 2024) period ended on 31 March 2024 would be BDT 0.30. (cont.1)

Nothing found..

Mon, 3rd February 2025

6:34 am

Dividend Disbursement

The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2024 to the respective shareholders.

Mon, 28th October 2024

4:04 am

Dividend Declaration

(Continuation news of TECHNODRUG): 160/A, Kakrail VIP Road, Dhaka 1000 and Digital Platform through the link https://technodrug.digitalagmbd.net. Record date: 18.11.2024. The Company has also reported EPS of Tk. 2.94, NAV per share with revaluation of Tk. 33.50, NAV per share without revaluation of Tk. 28.33 and NOCFPS of Tk. 4.48 for the year ended June 30, 2024 as against Tk. 2.08, Tk. 27.74, Tk. 22.57 and Tk. 2.23 respectively for the year ended June 30, 2023. (end)

Mon, 28th October 2024

4:04 am

Dividend Declaration

The Board of Directors has recommended 12% Cash Dividend only for general shareholders other than Board of Directors for the year ended June 30, 2024. Directors/ sponsor are holding 82,776,200 shares and General Public are holding 49,221,988 shares. Cash dividend payable to General Public is Tk. 59,066,386.00. Date of AGM: 26.12.2024, Time: 10:00 AM, Venue: The AGM will be conducted through Hybrid System in combination of Physical Presence at Institution of Diploma Engineers, (cont.)

Nothing found..

Wed, 23rd April 2025

6:29 am

Board Meeting schedule under LR 16(1)

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 29, 2025 at 4:30 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2025.

Mon, 27th January 2025

5:04 am

Board Meeting schedule under LR 16(1)

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 30, 2025 at 4:30 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2024.

Mon, 11th November 2024

5:09 am

Board Meeting schedule under LR 16(1)

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 14, 2024 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2024.

Mon, 21st October 2024

4:59 am

Board Meeting schedule under LR 19(1)

As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 27, 2024 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2024.

Nothing found..